Last kr103.00 SEK
Change Today -1.25 / -1.20%
Volume 196.4K
MVIRB On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
OTC US
Frankfurt
As of 11:30 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Open
kr104.00
Previous Close
kr104.25
Day High
kr105.75
Day Low
kr101.75
52 Week High
06/12/14 - kr151.00
52 Week Low
12/30/13 - kr82.50
Market Cap
3.2B
Average Volume 10 Days
182.6K
EPS TTM
kr32.14
Shares Outstanding
30.6M
EX-Date
--
P/E TM
3.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based specialty pharmaceutical company, develops and markets pharmaceuticals for the treatment of infectious diseases in the Nordic region. It focuses on the research and development of antiviral pharmaceuticals primarily in the hepatitis C area; and other areas, such as bone-related disorders and neuropathic pain. The company also supplies prescription pharmaceuticals, including 16 prescription pharmaceuticals in different therapeutic areas, including Mollipect, Teovent, and Theo-Dur in respiratory organs; Probecid for gout; Nitroglycerin BioPhausia, Digoxin BioPhausia, and Suscard for cardiovascular system; simeprevir for liver disease; Laxabon and Egazil for gastrointestinal system; Xerclear for cold sores; Lithionit and Adasuve for psychiatry; Paraflex for the musculoskeletal system; Citodon and Morfin Special for pain; and Solvezink for zinc deficiency. Medivir AB is headquartered in Stockholm, Sweden.

137 Employees
Last Reported Date: 11/20/14

medivir ab-b shs (MVIRB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medivir ab-b shs (MVIRB) Key Developments

Medivir AB Announces Earnings Results for the Third Quarter and Nine Months Ended September 2014

Medivir AB announced earnings results for the third quarter and nine months ended September 2014. For the quarter, the company reported net turnover of SEK 617.8 million compared to SEK 80.2 million a year ago. Revenues from Medivir's own pharmaceutical sales totalled SEK 100.8 million compared to SEK 36.6 million a year ago. Profit after tax was SEK 373.7 million or SEK 11.83 per diluted share compared to loss after tax of SEK 11.0 million or SEK 0.35 per diluted share a year ago. Cash flow from operating activities amounted to SEK 473.0 million compared to cash flow used in operating activities of SEK 5.2 million a year ago. For the quarter, the company reported net turnover of SEK 1,390.0 million compared to SEK 299.0 million a year ago. Revenues from Medivir's own pharmaceutical sales totalled SEK 210.2 million compared to SEK 210.2 million a year ago. Profit after tax was SEK 985.4 million or SEK 31.21 per diluted share compared to loss after tax of SEK 40.5 million or SEK 1.30 per diluted share a year ago. Cash flow from operating activities amounted to SEK 504.0 million compared to cash flow used in operating activities of SEK 32.5 million a year ago.

Medivir AB Announces U.S. Food and Drug Administration Approved Olysio(R) (simeprevir)

Medivir AB announced that the U.S. Food and Drug Administration (FDA) has approved Olysio(R) (simeprevir) in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C infection in adult patients as part of a combination antiviral treatment regimen. The sNDA was filed in May by Medivir's partner Janssen Research & Development LLC. Data supporting the Olysio(R) and sofosbuvir combination regimen are from the COSMOS study, an open-label, randomized phase II clinical trial that investigated the efficacy and safety of 12 or 24 weeks of Olysio(R) (150 mg once daily) in combination with sofosbuvir (400 mg once daily), with or without ribavirin in HCV genotype 1 chronically infected naïve and treatment-experienced adult patients with compensated liver disease. In the COSMOS study 95% of patients (20/21) with METAVIR F0-F3 (patients with no liver fibrosis to near cirrhotic liver disease) receiving 12 weeks of Olysio(R) with sofosbuvir achieved SVR12 (sustained virologic response 12 weeks after the end of treatment). Regardless of whether patients were treatment-naïve or treatment-experienced 86% of patients (6/7) with METAVIR F4 (cirrhosis) receiving 12 weeks of Olysio(R) in combination with sofosbuvir achieved SVR12, while 100% (10/10) of patients with cirrhosis who were treated with the combination for 24 weeks achieved SVR12. For all patients in the COSMOS trial (treatment-naïve and treatment-experienced, METAVIR F0-F4), 93% (26/28) achieved SVR12 after 12 weeks and 97% (30/31) achieved SVR12 after 24 weeks of treatment. In the COSMOS trial, the most common (> 10%) adverse reactions reported during 12 weeks of treatment with Olysio(R) in combination with sofosbuvir without ribavirin were fatigue (25%), headache (21%), nausea (21%), insomnia (14%) and pruritus (11%). Rash and photosensitivity were reported in 11% and 7% of patients, respectively. During 24 weeks of treatment, dizziness (16%), and diarrhea (16%) were also reported.

Medivir AB and County Councils Conclude Agreement on Olysio(R)-Based Treatment for Hepatitis C

Medivir AB announced that the company has entered into an agreement with Swedish county councils regarding the treatment of hepatitis C with Olysio(R) (simeprevir). Dental and Pharmaceutical Benefits Agency (TLV) has concluded that treatment with Olysio(R) (simeprevir) is beneficial from a health economics viewpoint in the treatment of HCV genotypes 1 and 4 with METAVIR scores of F3-F4, irrespective of previous treatment. A risk-sharing agreement between Medivir and the Swedish county councils has been drawn up in parallel with TLV's health economic evaluation. The agreement offers the county councils and Medivir an increased degree of predictability with regard to treatment costs and the use of Olysio(R), in that the risk-sharing applies both in relation to treatment results and to the number of patients who will be treated. Joint county council recommendations related to the use of Olysio(R) will be designed by the New Pharmaceutical Product Therapies (NLT) group (a group within the Swedish Association of Local Authorities and Regions tasked with evaluating new pharmaceutical products and therapies). The NLT group will have a meeting October the 30th regarding a protocol for structured introduction of Olysio(R).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr103.00 SEK -1.25

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies
 

Industry Analysis

MVIRB

Industry Average

Valuation MVIRB Industry Range
Price/Earnings 3.1x
Price/Sales 2.0x
Price/Book 1.7x
Price/Cash Flow 3.0x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit www.medivir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.